When to use Secondary Testing
Should only be used if results will alter therapy – usually addition of pharmacotherapy Left to the discretion of the clinician in consultation with the patient – type of testing reflects local availability and expertise (cost and expected yield should be considered) Multiple tests should not be routinely undertaken Annual or repeated assessment is not advocated Each test outlined provides incremental predictive value to FRS in terms of risk stratification A 'positive' test indicates that the calculated FRS may be erroneously low – treatment should be considered With the exception of hsCRP, or eGFR, the benefits of initiating statin therapy based on this approach has not yet been tested and thus has not yet been proven to improve CV outcomes

When to use Secondary Testing

Should only be used if results will alter therapy – usually addition of pharmacotherapy
Left to the discretion of the clinician in consultation with the patient – type of testing reflects local availability and expertise (cost and expected yield should be considered)
Multiple tests should not be routinely undertaken
Annual or repeated assessment is not advocated
Each test outlined provides incremental predictive value to FRS in terms of risk stratification
A 'positive' test indicates that the calculated FRS may be erroneously low – treatment should be considered
With the exception of hsCRP, or eGFR, the benefits of initiating statin therapy based on this approach has not yet been tested and thus has not yet been proven to improve CV outcomes